Skip to main content
Clinical Trials/NCT00621491
NCT00621491CompletedNot Applicable

Randomized Controlled Clinical Trial for Prevention of Thromboembolic Complications After Permanent Transvenous Leads Implantation in High-risk Patients

University of Sao Paulo1 site in 1 country101 target enrollmentStarted: February 2004Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
101
Locations
1
Primary Endpoint
Incidence of venous obstructions observed by digital subtraction venography

Study Overview

Brief Summary

The aim of this study was to compare the safety and efficacy of warfarin versus placebo, administered for 6 months, in the prevention of thromboembolic complications after transvenous cardiac devices implantation in high-risk patients.

Detailed Description

Venous lesions following cardiac devices implantation are a common complication of transvenous access that may cause disease manifestations and difficulties during reoperations. These lesions tend to develop early, and their incidence decreases gradually within 6 months after device implantation. Ventricular dysfunction and previous transvenous temporary leads ipsilateral to the permanent implant are risk factors identified in a previous study performed at our institution and other risk factors have been reported recently.The usefulness of prophylactic therapeutic strategies to prevent these complications, however,remains unknown. This randomized trial examined the effects of warfarin in the prevention of these complications in high-risk patients. After device implantation, patients were randomly assigned to receive either placebo or warfarin. Periodical clinical and laboratorial evaluations were performed to anticoagulant management. Following the six-month period, every patient was submitted to a digital subtraction venography.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 90 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • adults patients submitted to first transvenous implant of pacemakers, implantable cardioverter-defibrillator, or cardiac resynchronization therapy devices
  • left ventricular ejection fraction ≤0.40 and/or
  • previous transvenous temporary leads ipsilateral to the permanent device implant

Exclusion Criteria

  • history of venous thromboembolism
  • atrial fibrillation
  • coagulopathy or platelet disorder
  • malignancy
  • gastro-intestinal hemorrhage or active gastro-duodenal ulcer in the past 6 months
  • abnormal prothrombin time (PT)or an international normalized ratio (INR) >40%, or treated with oral anticoagulants

Arms & Interventions

1

Placebo Comparator

Single daily dose of Placebo during six months

Intervention: Warfarin (Drug)

Outcomes

Primary Outcomes

Incidence of venous obstructions observed by digital subtraction venography

Time Frame: Six months

Secondary Outcomes

  • Safety of anticoagulant therapy, morbidity and overall mortality(Six months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Roberto Costa

MD PhD, Associate Professor of Cardiovascular Surgery

University of Sao Paulo

Study Sites (1)

Loading locations...

Similar Trials